Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles, mumps, and rubella vaccine (Sanofi)
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The measles, mumps, and rubella (MMR) vaccine produced by Sanofi Pasteur (often branded as Trimovax) is a live-attenuated viral vaccine indicated for the active immunization of children and adults against measles, mumps, and rubella. It typically contains the Schwarz strain of the measles virus, the Urabe AM9 or Jeryl Lynn strain of the mumps virus, and the Wistar RA 27/3 strain of the rubella virus. In clinical development programs, Sanofi Pasteur has evaluated this vaccine's safety and immunogenicity when administered concomitantly with other pediatric vaccines, such as the tetravalent dengue vaccine (CYD-TDV, Dengvaxia) and the yellow fever vaccine (Stamaril). These studies aim to confirm that the co-administration of MMR does not negatively impact the seroconversion rates or safety profile of the dengue vaccine or other routine immunizations.
- Brand names
- Trimovax
- Other names
- MMR vaccineMeasles, Mumps, and Rubella Virus Vaccine Live
Beyond the preview
Go deeper on measles, mumps, and rubella vaccine (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles, mumps, and rubella vaccine (Sanofi).